静止的癌细胞通过形成免疫抑制来抵抗T细胞的攻击
Pilar Baldominos1, Alex Barbera-Mourelle2, Olga Barreiro3
1Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Cell
|April 21, 2022
概括
在三阴性乳腺癌 (TNBC) 中,静止癌细胞 (QCC) 通过创建抑制瘤微环境而抵抗免疫治疗. 针对这些QCC可以克服治疗耐药性并防止TNBC复发.
科学领域:
- 癌症学
- 免疫学
- 癌症生物学
背景情况:
- 免疫疗法对三阴性乳腺癌 (TNBC) 是有前途的.
- 患者复发表明免疫疗法耐药性的机制.
- 了解耐药性对于改善TNBC治疗结果至关重要.
研究的目的:
- 研究静止癌细胞 (QCC) 在TNBC免疫疗法耐药性的作用.
- 描述QCC集群中的瘤微环境.
- 确定导致TNBC免疫疗法耐药性的细胞机制.
主要方法:
- 使用具有空间分辨率的单细胞RNA测序.
- 在QCC位内外透的免疫细胞进行了分析.
- 转录组分析确定了细胞表型和基因表达模式.
主要成果:
- 静止癌细胞 (QCC) 形成集群,免疫细胞透率降低.
- QCC 具有增强的瘤生成潜力,并表达与化疗耐药性和干性相关的基因.
- 在QCC集群中,观察到缺氧的微环境,其中包括耗尽的T细胞,瘤保护性纤维细胞和功能障碍的树突细胞.
结论:
- 通过诱导缺氧,QCCs产生免疫抑制的瘤微环境,从而损害T细胞功能.
- 在TNBC中,QCC充当免疫疗法耐药性的储存体.
- 针对QCC提供了一种潜在的策略,以克服免疫疗法耐药性,并防止TNBC的疾病复发.
更多相关视频
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
740
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
7.6K
相关概念视频
Cancer Stem Cells and Tumor Maintenance
5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Tumor Immunotherapy
689
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
689
Stem Cell Niche
5.3K
The stem cell niche is the dynamic microenvironment where stem cells reside. Inside these niches, the cells may remain undifferentiated, undergo high self-renewal, or become lineage-specific progenitors. Stem cells coexist with other niche cells, such as stromal cells. They also interact closely with the ECM. Cell-cell and cell-matrix communication occur via adhesion molecules or soluble factors that signal the stem cells and determine their fate. Stromal cells also provide survival signals to...
5.3K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Multipotency of Hematopoietic Stem Cells
3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
